Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Leukemia

Hematologic Diseases

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer

Flow Cytometry

Adrian Padurean, MD

Mike Keeney

Joanne Luider

Wolfgang Kern

Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.

Multi-center study of specimens from subjects presenting for flow cytometry immunophenotyping as part of their standard of care for hematological diseases work-up. Residual specimens will be tested using the ClearLLab Panels to determine the presence or absence of an abnormal phenotype and compare results to clinical impression (hematological malignancy or non-malignancy).

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Presence or absence of an abnormal phenotype detected using the ClearLLab Panels vs. the clinical outcome of "Hematologically Malignant" or "Hematologically Non-Malignant" from the same subject

Beckman Coulter, Inc.

Heart and Blood Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Hematologic Neoplasms

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Gastrointestinal Agents

All Drugs and Chemicals

Bismuth

Antacids

Anti-Ulcer Agents

Placebo tablets, containing no active substance

1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy

Bismuth tablets

Placebo tablets

Per B Hansen, MD

The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.

Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?

Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? A Clinical, Prospective, Randomized, Blinded Examination of Patients Suffering From Hematological Malignancies Treated With Intensive Chemotherapy and/or Radiotherapy.

Copenhagen University Hospital at Herlev

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Evaluation of ClearLLab Leukemia and Lymphoma Panels	NCT03413644	Leukemia-Lympho...	Flow Cytometry	-	Beckman Coulter, Inc.
Evaluation of ClearLLab Leukemia and Lymphoma Panels	NCT03413644	Leukemia-Lympho...	Flow Cytometry	-	Beckman Coulter, Inc.
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?	NCT00892502	Hematological D... Hematological M... Blood Diseases Malignant Lymph... Leukemia Multiple Myelom...	Bismuth tablets Placebo tablets	18 Years - 75 Years	Copenhagen University Hospital at Herlev

Spots Global Cancer Trial Database for hematological diseases